Koo,

Hopefully these two investor conferences address some of the desired updates on the things that Stock alluded to earlier in the week in this post. Most likely only a major company update would necessitate a news release. It just seems like a perfect opportunity for some news to be released tomorrow morning that can then be presented in person at Bloom Burton & Co and at BioNetwork East.

Of most imminent interest are: 1) the next licensing deal that we've been told should be announced soon and 2) additional RVX-208 trials that are late in the planning stage (PNH and kidney), as well as more info on the liver fibrosis and muscular dystrophy indications that Ewelina alluded to in her NYAS presentation. It would be great to hear more details and more concrete timelines for these.

We've also heard about Resverlogix doing much pre-clinical work for additional drug candidates, so at some point we should expect to hear about them selecting another molecule to advance into human trials and also hear about what new indications they plan to go after with this new molecule.

BearDownAZ